Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Fineline Cube Jan 26, 2026
Company Drug

Ascentage Pharma Presents Positive Clinical Results for Olverembatinib and Lisaftoclax at EHA Meeting

Fineline Cube Jun 18, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has presented the results of...

Company

AstraZeneca Restructures County Oncology Team to Enhance Vertical Alignment

Fineline Cube Jun 18, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading global biopharmaceutical company, is planning to restructure and spin...

Company Drug

Nanjing Sanhome’s Oritinib Wins NMPA Approval for EGFR T790M Positive NSCLC

Fineline Cube Jun 18, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd has received approval from the National Medical Products Administration (NMPA)...

Company Drug

MicroPort Endovascular’s Vewatch Filter Gets NMPA Green Light for Pulmonary Embolism Prevention

Fineline Cube Jun 18, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced...

Company Drug

Kintor Pharmaceutical Initiates Phase II Clinical Trial for Acne Treatment GT20029 in China

Fineline Cube Jun 18, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the enrollment...

Company Drug

RemeGen’s Telitacicept Receives NMPA Approval for Clinical Trial in IgG4 Related Diseases

Fineline Cube Jun 18, 2024

RemeGen (HKG: 9995), a Chinese pharmaceutical company, has announced that it has received clinical trial...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for Breast Cancer Drug Combo

Fineline Cube Jun 18, 2024

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading pharmaceutical company in China, has announced that it...

Company Deals

Shineco Partners with Tuling Vision to Develop Intelligent Healthcare Solutions

Fineline Cube Jun 18, 2024

Shineco Inc. (NSDQ: SISI), a U.S.-based company, has signed a partnership deal with China-headquartered Tuling...

Company Deals

Wuxi’s Binhu District Partners with Fresenius Kabi to Boost Healthcare Services

Fineline Cube Jun 18, 2024

The Binhu District People’s Government of Wuxi, Jiangsu province, China, has entered into a partnership...

Company Drug

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Phase II Trial in Pancreatic Cancer

Fineline Cube Jun 18, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has announced...

Company Drug

Walvax Biotechnology Halts COVID-19 Vaccine Clinical Trials Citing Low Benefits

Fineline Cube Jun 18, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142), a biopharmaceutical company based in China, has announced the...

Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB518 Clinical Trial in Solid Tumors

Fineline Cube Jun 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Deals

Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development

Fineline Cube Jun 18, 2024

Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with...

Company Drug

BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US

Fineline Cube Jun 18, 2024

BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...

Company Drug

Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials

Fineline Cube Jun 18, 2024

Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...

Company Drug

Amgen’s Blincyto Secures New Indication Approval for B-ALL Consolidation Treatment in the US

Fineline Cube Jun 18, 2024

Amgen (NASDAQ: AMGN) has announced that its bispecific T-cell engager (BiTE) Blincyto (blinatumomab) has received...

Company Drug

MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma

Fineline Cube Jun 18, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company

AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer

Fineline Cube Jun 17, 2024

Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...

Company Drug

FDA Approves Broadened Use of BMS’ Next-Gen TKI Augtyro for Advanced Solid Tumors

Fineline Cube Jun 17, 2024

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...

Company Deals

CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally

Fineline Cube Jun 17, 2024

CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced...

Posts pagination

1 … 292 293 294 … 614

Recent updates

  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
  • Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge
  • MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification
  • Huahui Health’s Libevitug Wins NMPA Approval as World’s First HDV Antibody Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Company Drug

Sanofi’s Amlitelimab Hits Phase III Goals in Atopic Dermatitis, Targets Q4W/Q12W Dosing Edge

Medical Device

MicroPort Endovascular’s Talos Stent Graft Secures EU CE MDR Certification

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.